Ameriprise Financial Inc. Increases Stock Holdings in Humana Inc. $HUM

Ameriprise Financial Inc. increased its holdings in Humana Inc. (NYSE:HUM) by 13.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 199,932 shares of the insurance provider’s stock after acquiring an additional 23,608 shares during the quarter. Ameriprise Financial Inc. owned about 0.17% of Humana worth $52,918,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Cary Street Partners Investment Advisory LLC lifted its stake in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after acquiring an additional 46 shares during the period. Applied Finance Capital Management LLC lifted its stake in Humana by 1.7% in the first quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider’s stock worth $779,000 after acquiring an additional 48 shares during the period. Achmea Investment Management B.V. lifted its stake in Humana by 0.5% in the first quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider’s stock worth $2,746,000 after acquiring an additional 49 shares during the period. Beech Hill Advisors Inc. lifted its stake in Humana by 6.1% in the first quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider’s stock worth $229,000 after acquiring an additional 50 shares during the period. Finally, Townsquare Capital LLC lifted its stake in Humana by 2.8% in the first quarter. Townsquare Capital LLC now owns 2,255 shares of the insurance provider’s stock worth $597,000 after acquiring an additional 61 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM opened at $297.30 on Thursday. The stock has a 50-day moving average price of $252.05 and a 200-day moving average price of $254.08. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The firm has a market cap of $35.76 billion, a PE ratio of 22.82, a P/E/G ratio of 1.76 and a beta of 0.44. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $382.72.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analysts’ expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.Humana’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s payout ratio is currently 27.17%.

Analysts Set New Price Targets

Several brokerages have commented on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Raymond James Financial raised Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Bank of America lowered their price objective on Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a research report on Tuesday, June 17th. Piper Sandler lowered their price objective on Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research report on Thursday, July 31st. Finally, Truist Financial lowered their price objective on Humana from $280.00 to $260.00 and set a “hold” rating for the company in a research report on Wednesday, July 16th. Seven equities research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.